Rucaparib camsylateProduct ingredient for Rucaparib

Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair.¹ Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.^1,2

Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 ¹ and accelerated approval in December 2016.⁴ The drug was later approved by the European Commission in May 2018.⁷ It is currently used to treat recurrent ovarian and prostate cancer in adults.^6,7.

On December 17, 2025, the FDA granted regular approval to rucaparib for adults with a deleterious BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval.^9,10